AstraZeneca reports record-breaking quarter, says it can ‘absorb impact’ of US pricing dealnews2025-11-06T11:54:41+00:00November 6th, 2025|Endpoints News|
Lilly’s amylin moves to Phase 3 after success in next obesity drug wavenews2025-11-06T11:45:50+00:00November 6th, 2025|Endpoints News|
China lifts ban on Illumina’s DNA sequencersnews2025-11-06T03:19:41+00:00November 6th, 2025|Endpoints News|
Delaware judge refuses to block Metsera from ending Pfizer obesity dealnews2025-11-05T21:27:42+00:00November 5th, 2025|Endpoints News|
First Circuit hears arguments over NIH indirect cost cutsnews2025-11-05T20:29:34+00:00November 5th, 2025|Endpoints News|
FDA reviewers were divided over Stealth’s data before Barth drug approvalnews2025-11-05T20:15:07+00:00November 5th, 2025|Endpoints News|
FTC raises concerns about structure of Novo Nordisk’s bid for Metseranews2025-11-05T19:49:59+00:00November 5th, 2025|Endpoints News|
Supernus halts delivery of some Parkinson’s pumps over supply constraintsnews2025-11-05T18:05:08+00:00November 5th, 2025|Endpoints News|
Teva CEO says IRA drug price negotiations met expectationsnews2025-11-05T17:52:56+00:00November 5th, 2025|Endpoints News|
FDA rejects Biohaven’s ataxia drug, shutting down company’s second attempt to win approvalnews2025-11-05T16:39:16+00:00November 5th, 2025|Endpoints News|
